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Non-standard Abbreviations and Acronyms 
CHANCE Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular 
Events 
CHANCE-2 Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling 
Cerebrovascular Events II  
CI Confidence interval 
COMPASS Cardiovascular Outcomes for People Using Anticoagulation Strategies 
HR Hazard ratio  
PLATO PLATelet inhibition and patient Outcomes  
POINT Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke 
SOCRATES The Acute Stroke or Transient Ischaemic Attack Treated With Aspirin or 
Ticagrelor and Patient Outcomes  
THALES Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and 
Aspirin for Prevention of Stroke and Death 
TIA Transient ischemic attack 
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Transient ischemic attack (TIA) and minor stroke account for 30%-50% of all 
cerebral ischemic events around the world.1, 2 In the acute setting, mono antiplatelet 
therapy (aspirin) is better than none for prevention of recurrent stroke 3, 4, and dual 
antiplatelet therapy with aspirin and clopidogrel was superior to aspirin alone as seen 
in the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular 
Events (CHANCE) 5 and Platelet-Oriented Inhibition in New TIA and Minor 
Ischemic Stroke (POINT) 6 trials (Table 1). However, CYP2C19 genetic resistance to 
clopidogrel is present in 25-33% of individuals 7 and although there are functional 
tests such as P-selectin expression 8 that detect high residual platelet reactivity, they 
are not used routinely. Therefore, an adenosine diphosphate-receptor antagonist 
without genetic resistance, e.g. ticagrelor, might offer advantages.  
 
The Acute Stroke or Transient Ischaemic Attack Treated With Aspirin or Ticagrelor 
and Patient Outcomes (SOCRATES) trial 9 was the first phase III trial of ticagrelor in 
acute TIA/minor stroke but failed to show superiority over aspirin at preventing 
stroke, a finding similar to other mono-antiplatelet therapy comparisons 10, 11. 
However, a pre-specified subgroup analysis of SOCRATES reported that ticagrelor 
was more effective than aspirin in patients with ipsilateral atherosclerotic stenosis 
≥50%.12 
 
To test this secondary finding and, since previous dual versus mono antiplatelet 
therapy trials have been positive 5, 6, the Acute Stroke or Transient Ischemic Attack 
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Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) 
trial 13 compared ticagrelor plus aspirin with aspirin alone in preventing stroke or 
death in patients with a minor acute non-cardioembolic ischemic stroke (NIHSS ≤5) 
or TIA (either high risk or presence of ipsilateral atherosclerotic stenosis ≥50%) and 
without thrombolysis or thrombectomy (Table 1). With 11,016 enrolled patients, 
THALES found that aspirin plus ticagrelor was superior to aspirin alone for 
preventing the primary outcome of stroke or death by 30 days (5.5% vs. 6.6%, hazard 
ratio [HR]: 0.83, 95% confidence interval [CI]: 0.71-0.96) and stroke alone (HR 0.81, 
95% CI: 0.69–0.95) but not death. An increase in severe bleeding was seen with 
aspirin plus ticagrelor (0.5% vs. 0.1%, HR 3.99, 95% CI: 1.74-9.14), with this mainly 
driven by increased intracranial but not fatal bleeding; the increase in bleeding was 
present from 5 days after randomisation.14  
 
Several questions remain to be answered regarding THALES. First, the exclusion of 
patients receiving reperfusion therapy (inevitable because of the 24 hour inclusion 
window) makes interpretation of the results difficult for those patients with large 
vessel occlusion (the proportion of these is so far unreported). Second, the loading 
dosage of aspirin was much higher than in CHANCE and POINT and this may have 
contributed to increased bleeding (as also seen in the PLATelet inhibition and patient 
Outcomes (PLATO) trial in patients with an acute coronary syndrome 15). Although 
POINT also found an increased risk of major hemorrhage with aspirin and clopidogrel 
given for 90 days, a pooled analysis of CHANCE and POINT revealed that the 
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treatment effect of aspirin and clopidogrel was mostly achieved in the first 21 days 
without an increased risk of severe bleeding.16 Hence, an analysis of severe bleeding 
by time from randomisation is needed to determine the optimal duration for aspirin 
plus ticagrelor. THALES has not yet reported results for the subgroup of patients with 
ipsilateral atherosclerotic stenosis ≥50%, important since 3 months of aspirin plus 
clopidogrel are recommended for symptomatic severe intracranial stenosis.17 Third, 
aspirin may not be the most appropriate comparator for trials in acute TIA and minor 
stroke. Whether aspirin plus ticagrelor is superior to aspirin plus clopidogrel remains 
unknown. In indirect comparisons, aspirin and ticagrelor in THALES had a 
significantly lower rate of stroke (5.14% vs. 6.54%, P=0.002 ) and ischemic stroke 
(5.00% vs. 6.30%, P=0.004 ) than aspirin plus clopidogrel in both CHANCE and 
POINT but with similar moderate to severe bleeding rates (0.65% vs. 0.60%, 
P=0.727). Further randomized clinical trials are warranted to directly compare aspirin 
plus ticagrelor with aspirin plus clopidogrel in patients with minor stroke or high-risk 
TIA. 
 
Dual antiplatelet therapy is better than monotherapy but triple antiplatelet therapy 
(aspirin, clopidogrel, dipyridamole) was not better still due to increased bleeding.18 
Ticagrelor is already licensed for acute coronary syndrome15 and presumably will 
become available for use after minor stroke and TIA. However, it should not be used 
long term since other dual combinations are safe, e.g. aspirin plus cilostazol 19, and 
aspirin plus dipyridamole20. 
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Whether THALES should lead to a change in practice to using aspirin and ticagrelor 
first line, or just as an option in high risk patients who fail aspirin plus clopidogrel or 
those with clopidogrel resistance, remains unclear. The Clopidogrel With Aspirin in 
High-risk Patients With Acute Non-disabling Cerebrovascular Events II (CHANCE-2) 
trial (NCT04078737) is testing dual therapy in those with clopidogrel resistance. The 
THALES regime may be most relevant in non-cardioembolic ischemic stroke patients 
with NIHSS 4-5 or with ipsilateral atherosclerotic stenosis ≥50%. The changeover 
from the THALES regime to maintenance therapy will depend on patient 
characteristics and national guidelines; possible strategies include monotherapy with 
aspirin,3, 4 clopidogrel or cilostazol alone, or combinations of aspirin and 
dipyridamole 20 or aspirin and cilostazol.19 The combination of aspirin and 
rivaroxaban, as tested in the Cardiovascular Outcomes for People Using 
Anticoagulation Strategies (COMPASS) trial is not relevant since it did not enroll 
patients with recent stroke. Many questions remain beyond the THALES trial and a 
pooled analysis of individual patient data from CHANCE, POINT and THALES will 
provide more evidence for dual antiplatelet therapy in patients with minor stroke or 
high-risk TIA in future.  
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Table 1. Summary of milestone trials of dual antiplatelet therapy in minor stroke and high risk transient ischemic attack 
  CHANCE 5 POINT 6 THALES 13,14 
Country (publication 
year) 
China (2013) 10 countries (2018) 28 countries (2020) 
Sample size 5,170 4,881 11,016 
Onset to randomization ≤24 h ≤12 h ≤24 h 
Definition of minor 
stroke  
NIHSS ≤3  NIHSS ≤3 NIHSS ≤5 
Definition of high-risk 
TIA 
ABCD2 ≥4 ABCD2 ≥4 ABCD2 ≥6  
Additional inclusion 
criteria 
-- -- Ipsilateral atherosclerotic 
stenosis ≥50% 
Dosage Clopidogrel: d1: 300mg; d2-
d90: 75 mg/d; 
Aspirin: d1: 75-300 mg; d2-
d21: 75 mg/d; 
Clopidogrel: d1: 600mg; d2-
d90: 75 mg/d; 







21 days  90 days 30 days 
Follow-up duration 90 days 90 days 30 days 
Primary outcome Stroke 
HR 0.68 (0.57-0.81) 
Ischemic stroke, myocardial 
infarction, and ischemic vascular 
death HR 0.75 (0.59-0.95) 
Stroke or death 
HR 0.83 (0.71-0.96);  
Safety outcome Severe bleeding  
HR 0.94 (0.24-3.79) 
Major hemorrhage 
HR 2.32 (1.10-4.87) 
Severe bleeding 
HR 3.99 (1.74-9.14) 
 
